Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3553 - Long-term follow-up results of stage III-IV non-small-cell lung cancer (NSCLC) patients treated with an epitope derived from Indoleamine 2,3 Dioxygenase (IDO) in a phase I study

Date

09 Sep 2017

Session

Poster display session

Presenters

Julie Kjeldsen

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

J.W. Kjeldsen1, T.Z. Iversen2, L.E. Noerregaard2, A. Mellemgaard2, M.H. Andersen1, I. Svane1

Author affiliations

  • 1 Department Of Hematology And Department Of Oncology, Herlev Hospital, University Of Copenhagen, Center for Cancer Immune Therapy, Herlev Hospital, 2730 - Herlev/DK
  • 2 Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
More

Resources

Abstract 3553

Background

A long-term follow up on an earlier published clinical trial of 15 stage III-IV NSCLC patients treated with and IDO peptide vaccine.1

Methods

15 patients with stage III-IV NSCLC in disease stabilization after standard chemotherapy were treated with subcutaneous vaccinations (100 µg IDO5 peptide, seq ALLEIASCL, in 900 µl Montanide). Patients were enrolled from 2010 to 2012 and treated biweekly for 2.5 months and thereafter monthly until progression or up to 5 years. As published in Clin Cancer Res 2013, the vaccine was well tolerated and a long-lasting PR + SD (>8.5 months) was seen in 47% of the patients. A long-term follow-up has been made, investigating the long term clinical benefit and immunity.

Results

3 of the 15 patients are still alive (May 2017) corresponding to a 5-year overall survival of 20%. One was excluded due to progression after 11 months; the other two have continued vaccination for 5 years and have both received 56 vaccines in total. One of the two patients developed a partial response of target lesions in the liver 15 months after the first vaccine and has been in stable disease ever since. The other patient had a solitary metastasis in a retroperitoneal gland at baseline and at the 1st evaluation scan the patient had no sign of malignancy and has been tumour free ever since. The vaccine was well tolerated for all 5 years. Analyses of PBMCs every 3rd to 6th month during treatment of the two long-term responders demonstrated a stable CD8+ T-cell population. The percentage of NK cells, MDSCs and Tregs were stable over time, demonstrating no sign of toxicity of the immune cells in the blood. Presence of IDO-specific CD8+ T cells were demonstrated by IFN-γ Elispot and could be detected in both patients at several time points during vaccinations.

Conclusions

The vaccine was well tolerated with no severe toxicity for administration up to five years. Two of 15 patients are long-term survivors with ongoing clinical response five years after 1. vaccination. 1. Iversen, T. Z. et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin. Cancer Res. 20, 221–232 (2014).

Clinical trial identification

NCT01219348

Legal entity responsible for the study

Herlev and Gentofte Hospital, Center for Cancer Immune Therapy, Department of Hematology and Oncology, Denmark

Funding

IO Biotech, Denmark

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.